Epclusa and Abilify drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Epclusa (sofosbuvir; velpatasvir) and Abilify (aripiprazole). Common drug interactions include encephalopathy among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Epclusa and Abilify. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Epclusa?

Epclusa has active ingredients of sofosbuvir; velpatasvir. eHealthMe is studying from 12,120 Epclusa users. Check the latest studies of Epclusa.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,456 Abilify users. Check the latest studies of Abilify.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

29 people who take Epclusa and Abilify together, and have interactions are studied.

What are the common drug interactions of Epclusa and Abilify, by gender? *:

female:

Encephalopathy (functioning of the brain is affected by some agent or condition)
Drug abuse
Headache (pain in head)
Somnolence (a state of near-sleep, a strong desire for sleep)
Abdominal pain upper
Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
Blood pressure fluctuation
Constipation
Delirium (wild excitement)
Drug withdrawal syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation)

male:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Osteonecrosis (death of bone)
Renal failure (kidney dysfunction)
Tooth loss
Vision blurred
Ascites (accumulation of fluid in the abdominal cavity)
Decreased appetite
Drug ineffective
Drug resistance (reduction in effectiveness of a drug)

What are the common drug interactions of Epclusa and Abilify, by age (0-1 to 60+)? *:

0-1:

Drug withdrawal syndrome neonatal (prenatal nas is caused by discontinuation of drugs taken by the pregnant mother)
Foetal exposure during pregnancy (exposing your unborn child to contraindicated in pregnancy leads birth defect)
Premature baby

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Drug ineffective
Fatigue (feeling of tiredness)
Memory impairment
Muscular weakness (muscle weakness)
Vision blurred

50-59:

Anxiety
Bone density decreased
Emotional distress
Pain
Bone loss
Chronic kidney disease
Dysuria (painful or difficult urination)
Fatigue (feeling of tiredness)
Nephrolithiasis (calculi in the kidneys)
Osteonecrosis (death of bone)

60+:

Ascites (accumulation of fluid in the abdominal cavity)
Biliary dilatation
Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
Diarrhoea
Gallbladder polyp (growths or lesions resembling growths (polypoid lesions) in the wall of the gallbladder)
Nausea (feeling of having an urge to vomit)
Pleuritic pain
Rash pruritic (redness with itching)
Vomiting

What are the existing conditions these people have? *

Hepatitis C: 6 people, 20.69%
Hiv Infection: 3 people, 10.34%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Epclusa and Abilify?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously